Monash University and ClinChoice Inc have announced a new partnership to speed up early-stage clinical trials and help bring new medical discoveries to patients faster around the world.
Both organizations bring their own strengths to healthcare innovation and share a common goal of improving the health and well-being of people globally.
The partnership brings together the strong research and clinical expertise of Monash University with the global development, regulatory, and data science skills of ClinChoice Inc. Together, they aim to support high-quality research that focuses on patient needs in Australia and around the world.
Their main goal is to speed up early-stage clinical trials and help deliver new and innovative treatments to patients more quickly.
“Monash is deeply committed to pursuing impact-driven partnerships that leverage our expertise in research and healthcare innovation,” said Professor Robyn Ward AM, Deputy Vice-Chancellor (Research and Enterprise). “We’re proud to partner with ClinChoice. By combining our research excellence with their global capability, we can bring new therapies and technologies to patients while strengthening collaboration between our talented researchers with the global biotechnology sector.”
“We are honored to formalize this partnership with Monash University, a globally respected institution at the forefront of pharmaceutical science,” said Kevin Xu, Chairman and CEO of ClinChoice, “This collaboration is a strong testament to ClinChoice’s mission to support innovation through academic and clinical partnerships.”
“By combining our global development experience with Monash’s research excellence, we will advance clinical research in an even more efficient and impactful manner, ultimately bringing new therapies to patients faster,” added Kerry Dyson, President, International Clinical Operations at ClinChoice.
Monash University is one of the top research universities in Australia and is well known globally for its work in pharmaceutical sciences and pharmacology. It is ranked among the world’s top 50 universities in major rankings like QS World University Rankings 2026, QS Sustainability Rankings 2026 and US News Best Global Universities 2025–26. The university is also ranked 3rd in Pharmacy and Pharmaceutical Sciences and 4th in Pharmacy and Pharmacology worldwide.
Through the Monash Institute of Pharmaceutical Sciences (MIPS), Monash focuses on creating new medical solutions, from early research to real-world treatments. The university is known for combining strong scientific research with industry partnerships, helping turn discoveries into practical healthcare solutions that benefit patients.
ClinChoice Inc is a global clinical research company that works with pharmaceutical and biotechnology firms to turn scientific ideas into real treatments for patients. It has over 30 years of experience and operates in more than 15 countries across North America, Europe, and the Asia-Pacific region.
The company has strong expertise in areas like cancer (hematology/oncology), immune system diseases, heart and metabolic conditions, and brain-related disorders. ClinChoice has completed over 3,000 studies worldwide and is known for delivering both early-stage and late-stage clinical trials with speed, quality, and innovation.
Read More- Toy manufacturing startup BIDSO secures $6.7 million Series A round
